Arbutus Biopharma (ABUS) Research & Development (2013 - 2026)

Arbutus Biopharma (ABUS) has reported Research & Development for 14 consecutive years, with $4.1 million the latest figure, recorded in Q1 2026.

• Quarterly Research & Development fell 54.01% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.4 million (down 57.13% YoY) and the FY2025 annual result came in at $25.2 million, down 53.29% from the prior year.
• Research & Development fell to $4.1 million in Q1 2026 per ABUS's latest filing, from $5.0 million in the prior quarter.
• Over the last five years, Research & Development for ABUS reached as high as $22.9 million in Q4 2022 and fell as low as $4.1 million in Q1 2026.
• A 5-year average of $14.2 million and a median of $15.6 million in 2024 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development jumped 45.21% — and 2025, when it slumped 64.65%.
• Year by year, Research & Development stood at $22.9 million in 2022, then retreated by 23.47% to $17.6 million in 2023, then tumbled by 49.84% to $8.8 million in 2024, then slumped by 43.18% to $5.0 million in 2025, then fell by 17.7% to $4.1 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $4.1 million, $5.0 million, and $5.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.